Nouscom AG domiciled in Basel closed a EUR 12 million Series A financing co-led by LSP and and Versant Ventures. Nouscom’s technology focuses on viral vectors and oncolytic viruses, which infect and kill tumor cells and stimulate an immune response against cancer cells throughout the body. VISCHER advised Nouscom since foundation and in this financing round. The team at VISCHER was led by Dr. Matthias Staehelin (Partner, Corporate) with Nadia Tarolli (Partner, Tax) and Moritz Jäggy (Senior Associate, Corporate).